Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An announcement from Voyager Therapeutics ( (VYGR) ) is now available.
On February 9, 2026, Voyager Therapeutics, Inc. disclosed that Chief Medical Officer Toby Ferguson, M.D., Ph.D. had tendered his resignation from the company and all subsidiary roles, effective February 20, 2026, to pursue a new opportunity. The company stated that his departure was not due to any disagreement with Voyager, and President and Chief Executive Officer Alfred W. Sandrock, Jr., M.D., Ph.D. will assume key medical and strategic responsibilities for the clinical development portfolio on an interim basis, signaling a leadership transition but continuity in oversight of ongoing programs.
The move places additional operational and strategic duties on Sandrock as Voyager advances its pipeline, underscoring the importance of maintaining momentum in clinical development during the executive transition. While the company framed the change as amicable, stakeholders will be watching how the interim redistribution of responsibilities affects the execution and timing of Voyager’s development initiatives.
The most recent analyst rating on (VYGR) stock is a Buy with a $25.00 price target. To see the full list of analyst forecasts on Voyager Therapeutics stock, see the VYGR Stock Forecast page.
Spark’s Take on VYGR Stock
According to Spark, TipRanks’ AI Analyst, VYGR is a Neutral.
The score is primarily constrained by weak financial performance, driven by declining revenue, persistent losses, and negative operating/free cash flow. Technical signals are neutral-to-soft, offering limited support, while valuation is pressured by negative earnings and no dividend yield data.
To see Spark’s full report on VYGR stock, click here.
More about Voyager Therapeutics
Voyager Therapeutics, Inc. is a biotechnology company focused on developing gene therapies and neurologic medicines. The company operates in the biopharmaceutical industry, concentrating on clinical development programs aimed at treating neurological and other serious diseases.
Average Trading Volume: 539,338
Technical Sentiment Signal: Strong Sell
Current Market Cap: $205.7M
See more insights into VYGR stock on TipRanks’ Stock Analysis page.